{"id":45753,"date":"2022-07-01T17:02:06","date_gmt":"2022-07-01T15:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/"},"modified":"2022-07-01T17:02:06","modified_gmt":"2022-07-01T15:02:06","slug":"global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/","title":{"rendered":"Global Severe Hypertriglyceridemia Industry Report to 2032 &#8211; Insights, Epidemiology and Market Forecasts &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5523811\/severe-hypertriglyceridemia-shtg-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=grxkh6&amp;utm_campaign=1720880+-+Global+Severe+Hypertriglyceridemia+Industry+Report+to+2032+-+Insights%2C+Epidemiology+and+Market+Forecasts&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Severe Hypertriglyceridemia (SHTG) &#8211; Market Insight, Epidemiology and Market Forecast &#8211; 2032&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report deliver an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.\n<\/p>\n<p>\nThe Severe Hypertriglyceridemia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Severe Hypertriglyceridemia market size from 2019 to 2032. The Report also covers current Severe Hypertriglyceridemia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.\n<\/p>\n<p>\n<strong>Geography Covered<\/strong>\n<\/p>\n<ul>\n<li>\nThe United States\n<\/li>\n<li>\nEU5 (Germany, France, Italy, Spain, and the United Kingdom)\n<\/li>\n<li>\nJapan\n<\/li>\n<\/ul>\n<p>\n<strong>Study Period:<\/strong> 2019-2032\n<\/p>\n<p>\n<strong>Key Findings<\/strong>\n<\/p>\n<ul>\n<li>\nTotal prevalent cases of hypertriglyceridemia in the 7MM were found to be approximately 154,013,879 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).\n<\/li>\n<li>\nAmong 7MM, the United States has the highest prevalent cases of hypertriglyceridemia with 67,562,886 cases in 2021.\n<\/li>\n<li>\nAssessments as per the analysts show that total diagnosed prevalent cases of hypertriglyceridemia in the 7MM were approximately 69,306,246 in 2021.\n<\/li>\n<li>\nThe total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM were observed to be 3,465,312 in 2021. These cases are expected to increase during the forecasted period (2022-2032).\n<\/li>\n<li>\nThe highest diagnosed prevalent cases of severe hypertriglyceridemia were observed in the US as compared to EU-5 and Japan in the year 2021 and these cases are expected to increase in the forecast period.\n<\/li>\n<li>\nAmong the European countries, Germany had the highest diagnosed prevalent population of severe hypertriglyceridemia with 365,335 cases, followed by the UK with 277,161 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.\n<\/li>\n<li>\nIn Japan, 563,272 diagnosed prevalent cases of were recorded in the year 2021, accounting for 16.25% in 7MM.\n<\/li>\n<li>\nAs per the publisher&#8217;s assessment, for severe hypertriglyceridemia, the etiology-specific distribution of the disease suggests secondary type predominance in the US.\n<\/li>\n<\/ul>\n<p>\n<strong>Scope of the Report<\/strong>\n<\/p>\n<ul>\n<li>\nThe report covers the descriptive overview of Severe Hypertriglyceridemia, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.\n<\/li>\n<li>\nComprehensive insight has been provided into the Severe Hypertriglyceridemia epidemiology and treatment.\n<\/li>\n<li>\nAdditionally, an all-inclusive account of both the current and emerging therapies for Severe Hypertriglyceridemia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.\n<\/li>\n<li>\nA detailed review of the Severe Hypertriglyceridemia market; historical and forecasted is included in the report, covering the 7MM drug outreach.\n<\/li>\n<li>\nThe report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Severe Hypertriglyceridemia market.\n<\/li>\n<\/ul>\n<p>\n<strong>Report Highlights<\/strong>\n<\/p>\n<ul>\n<li>\nThe robust pipeline with novel MOA and oral ROA and increasing diagnosed prevalence will positively drive the Severe Hypertriglyceridemia market.\n<\/li>\n<li>\nThe companies and academics are working to assess challenges and seek opportunities that could influence Severe Hypertriglyceridemia R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.\n<\/li>\n<li>\nMajor players are involved in developing therapies for Severe Hypertriglyceridemia. The launch of emerging therapies will significantly impact the Severe Hypertriglyceridemia market.\n<\/li>\n<li>\nOur in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.\n<\/li>\n<\/ul>\n<p>\n<strong>Severe Hypertriglyceridemia Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nPatient Population\n<\/li>\n<li>\nTherapeutic Approaches\n<\/li>\n<li>\nSevere Hypertriglyceridemia Pipeline Analysis\n<\/li>\n<li>\nSevere Hypertriglyceridemia Market Size and Trends\n<\/li>\n<li>\nMarket Opportunities\n<\/li>\n<li>\nImpact of upcoming Therapies\n<\/li>\n<\/ul>\n<p>\n<strong>Severe Hypertriglyceridemia Report Key Strengths<\/strong>\n<\/p>\n<ul>\n<li>\n11-Years Forecast\n<\/li>\n<li>\nThe 7MM Coverage\n<\/li>\n<li>\nSevere Hypertriglyceridemia Epidemiology Segmentation\n<\/li>\n<li>\nKey Cross Competition\n<\/li>\n<li>\nHighly Analyzed Market\n<\/li>\n<li>\nDrugs Uptake\n<\/li>\n<\/ul>\n<p>\n<strong>Severe Hypertriglyceridemia Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nCurrent Treatment Practices\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nMarket Attractiveness\n<\/li>\n<li>\nMarket Drivers and Barriers\n<\/li>\n<li>\nSWOT analysis\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nThe report will help in developing business strategies by understanding trends shaping and driving Severe Hypertriglyceridemia.\n<\/li>\n<li>\nTo understand the future market competition in the Severe Hypertriglyceridemia market and an Insightful review of the key market drivers and barriers.\n<\/li>\n<li>\nOrganize sales and marketing efforts by identifying the best opportunities for Severe Hypertriglyceridemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\n<\/li>\n<li>\nIdentification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.\n<\/li>\n<li>\nOrganize sales and marketing efforts by identifying the best opportunities for the Severe Hypertriglyceridemia market.\n<\/li>\n<li>\nTo understand the future market competition in the Severe Hypertriglyceridemia market.\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5523811\/severe-hypertriglyceridemia-shtg-market?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=grxkh6&amp;utm_campaign=1720880+-+Global+Severe+Hypertriglyceridemia+Industry+Report+to+2032+-+Insights%2C+Epidemiology+and+Market+Forecasts&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/meyaaq<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;&#x63;&#x68;&#x61;&#110;&#100;&#109;&#97;&#114;&#107;&#101;&#116;&#115;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">pre&#115;&#115;&#64;&#x72;&#x65;&#x73;&#x65;&#x61;&#x72;cha&#110;&#100;&#109;&#97;&#x72;&#x6b;&#x65;&#x74;&#x73;&#x2e;com<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Severe Hypertriglyceridemia (SHTG) &#8211; Market Insight, Epidemiology and Market Forecast &#8211; 2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report deliver an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45753","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Severe Hypertriglyceridemia (SHTG) &#8211; Market Insight, Epidemiology and Market Forecast &#8211; 2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report deliver an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-01T15:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Severe Hypertriglyceridemia Industry Report to 2032 &#8211; Insights, Epidemiology and Market Forecasts &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-07-01T15:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/\"},\"wordCount\":841,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005318\\\/en\\\/1503275\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/\",\"name\":\"Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005318\\\/en\\\/1503275\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-07-01T15:02:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005318\\\/en\\\/1503275\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220701005318\\\/en\\\/1503275\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Severe Hypertriglyceridemia Industry Report to 2032 &#8211; Insights, Epidemiology and Market Forecasts &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Severe Hypertriglyceridemia (SHTG) &#8211; Market Insight, Epidemiology and Market Forecast &#8211; 2032&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report deliver an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-01T15:02:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Severe Hypertriglyceridemia Industry Report to 2032 &#8211; Insights, Epidemiology and Market Forecasts &#8211; ResearchAndMarkets.com","datePublished":"2022-07-01T15:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/"},"wordCount":841,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/","name":"Global Severe Hypertriglyceridemia Industry Report to 2032 - Insights, Epidemiology and Market Forecasts - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg","datePublished":"2022-07-01T15:02:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220701005318\/en\/1503275\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-severe-hypertriglyceridemia-industry-report-to-2032-insights-epidemiology-and-market-forecasts-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Severe Hypertriglyceridemia Industry Report to 2032 &#8211; Insights, Epidemiology and Market Forecasts &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45753"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45753\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}